Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 November 2020 | Story Ruan Bruwer | Photo Varsity Sports
Lefébre Rademan, the country’s top student netball player in 2019, has been snatched up by English netball club London Pulse to play in England in 2021.

 

Attempting to become an even better netballer, former Kovsies netball captain Lefébre Rademan decided to jet off to England to play in their league.

Rademan was contracted by London Pulse to compete in the European Superleague in 2021. She will be the fourth Kovsie after Maryka Holtzhausen (2015 and 2018-2019), Karla Pretorius (2016), and Khanyisa Chawane (2020) to play in the league.

Rademan said it was an easy decision, even though it will be far and a long time away from home. The league runs from February to July, with a pre-season in December. She will continue with her master’s degree at the University of the Free State next year.

“I am not going to play netball forever and such an opportunity doesn’t come often. Having competed against England, New Zealand, and Jamaica earlier in the year, I realised they play at a much higher level and if I want to improve and become the best, I would also need to move to a next level.”

“As a goal attack, having Protea teammate Sigi Burger (goal shooter) at the same club, will be an advantage for both of us and for the Proteas as a combination.”

Rademan has had a great past two years, making her Protea debut (12 tests in total) and receiving a number of accolades, such as the Varsity Netball Player of the Tournament in 2019.

In the Telkom Netball League in October, captaining the Free State Crinums, she was named Shooter of the Tournament. She was Player of the Match twice. Her goal average of 88,1% was the highest in the competition.

“Last year was such a good year for me personally, but that remains in the past. You can’t become complacent. I want to keep working hard and become a much better player,” Rademan said.

 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept